No Carolina / NY / Florida
Ph: 561.316.3330

Akadeum Life Sciences Announces Two New Microbubble Kits at Advanced Therapies Week

he Human T Cell Selection, Activation, and Expansion and Human T Cell Depletion kits use Akadeum’s BACS(TM) microbubbles to streamline cell therapy workflows.

Summation

  • Today, Akadeum Life Sciences, the market leader in buoyancy-based cell separation is announcing the release of a Human T Cell Selection, Activation, and Expansion Kit (GMP Grade), and a Human T Cell Depletion Kit (GMP Grade) at the Advanced Therapies Week on Jan 16.
  • The Human T Cell Selection, Activation, and Expansion and Human T Cell Depletion kits will provide CDMOs, cell and gene therapy companies, and researchers the improved cell therapy workflows and cost-savings that existing methods of cell separation cannot provide.
  • The kit beats the efficiency of magnetic methods of selection, activation, and expansion by providing reduced cell exhaustion, increased numbers of activated T cell populations, and a highly scalable solution that fits into a variety of cell therapy workflows.

Akadeum Life Sciences

Today, Akadeum Life Sciences, the market leader in buoyancy-based cell separation is announcing the release of a Human T Cell Selection, Activation, and Expansion Kit (GMP Grade), and a Human T Cell Depletion Kit (GMP Grade) at the Advanced Therapies Week on Jan 16. The kits add to Akadeum’s market-leading product portfolio in flotation-based technology, taking the company’s products one step further toward clinical trials.

2024 CAR T Cell Therapy Cost

In 2024, CAR T cell therapy can cost anywhere between $500,000 and $1 million per patient, predominantly because of the steep expense that existing manufacturing processes like magnets and columns require. The Human T Cell Selection, Activation, and Expansion and Human T Cell Depletion kits will provide CDMOs, cell and gene therapy companies, and researchers the improved cell therapy workflows and cost-savings that existing methods of cell separation cannot provide.

Unlike microbubbles, magnetic beads and columns are limited in their selection capacity and can damage more sensitive cell types, potentially decreasing cell viability and risking population integrity.

The Human T Cell Selection, Activation, and Expansion kit

The Human T Cell Selection, Activation, and Expansion kit isolates and extracts highly pure populations of T cells and activates them for use in cell therapy workflows. By mixing the product into a sample, microbubbles positively select and bind to cells expressing CD3 and CD28, gently floating them to the surface of the mixture. The kit beats the efficiency of magnetic methods of selection, activation, and expansion by providing reduced cell exhaustion, increased numbers of activated T cell populations, and a highly scalable solution that fits into a variety of cell therapy workflows.

The Human T Cell Depletion Kit

The Human T Cell Depletion kit removes non-gene-edited cells from CAR T manufacturing cultures. The product positively selects unwanted T cells, leaving a highly pure and untouched sample of engineered cells ready for downstream formulation. The robust depletion kit allows for the increased recovery of gene-edited cells and maintains the improved health of the cell therapy product.

Casey Wegner, Vice President of R&D at Akadeum comments…

“Our innovative new GMP-compliant separation kits not only yield an unparalleled number of healthy cells, but provide a quicker and more cost-effective solution, expanding the horizon of possibility for researchers currently limited by time and cost constraints.”

“Cell and gene therapy companies utilizing magnetic beads and columns in their workflows will now be at a competitive disadvantage. Harnessing the power of gravity, Akadeum’s eco-friendly, gentle flotation technology rapidly produces healthy cells, empowering researchers to increase the accessibility and efficiency of CAR T cell therapy.”

More News

Unleashing Biotech Potential: ATLATL Scientific & Miltenyi Biotec Partnership

Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy